Trial Profile
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Sep 2022
Price :
$35
*
At a glance
- Drugs Brilacidin (Primary)
- Indications COVID-19 respiratory infection
- Focus Therapeutic Use
- Sponsors Innovation Pharmaceuticals
- 07 Mar 2022 Results presented in an Innovation Pharmaceuticals Media Release.
- 25 Oct 2021 According to an Innovation Pharmaceuticals media release, the company anticipates reporting topline results from this trial in the week of November 8th .
- 13 Aug 2021 According to an Innovation Pharmaceuticals media release, topline results from this trial are anticipated to be available one week after database lock, with full analysis to follow.